Legal Representation
Attorney
Victoria D Summerfield
USPTO Deadlines
Next Deadline
78 days remaining
Non-Final Action Mailed
Due Date
October 21, 2025
Extension Available
Until January 21, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
9 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Jul 21, 2025 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
Jul 21, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Jul 21, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Jul 21, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
Jul 21, 2025 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | Loading... |
Jul 18, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Jul 10, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Feb 11, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
Feb 11, 2025 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Pharmaceutical research services; Pharmaceutical drug development and discovery services, namely, providing translational research tools and services for screening, testing, sequencing, and analysis of DNA- and RNA-encoded genetic material for drug candidate development; cell and gene therapy product development services; Analytical services for drug substance and drug product characterization which are for research use and in accordance with Good Manufacturing Practices (GMP); Preclinical services including pharmacology, pharmacokinetics, and toxicology in well established lab animal models; Research and development and Good Laboratory Practices (GLP) services for bioanalytical testing including immunogenicity, biodistribution and shedding to support pre-clinical (animal) and clinical (human) studies; Chemistry, Manufacturing, and Controls (CMC) laboratory and stability testing and analytical services in the fields of therapeutic drug evaluation and development, bioanalytical testing, immunogenicity testing, clinical studies, pre-clinical studies pharmacology, pharmacokinetics, and toxicology; Good Manufacturing Practices (GMP) laboratory and stability testing and analytical services in the fields of therapeutic drug evaluation and development, bioanalytical testing, immunogenicity testing, clinical studies, pre-clinical studies pharmacology, pharmacokinetics, and toxicology; Providing laboratory services for others in accordance with the Clinical Laboratory Improvement Amendments (CLIA) program; Research and development relating to production and analysis of viral-based vectors, pharmaceuticals, biologics, vaccines, biotechnological products, and gene and cell therapy preparations for use in medical research for others; Manufacturing services for others in the fields of viral-based and non-viral vectors, pharmaceuticals, biologics, vaccines, biotechnological products, and gene and cell therapy preparations
First Use Anywhere:
Oct 1, 2024
First Use in Commerce:
Oct 1, 2024
Additional Information
Pseudo Mark
FRANKLIN BIOLABS WORDMARK WITHOUT CLAIM TO FONT STYLE COLOR OR SIZE
Classification
International Classes
042